ClinVar Miner

Submissions for variant NM_000169.2(GLA):c.639+919G>A (rs199473684)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000844706 SCV000203980 pathogenic Fabry disease; Hypertrophic cardiomyopathy 2018-04-03 criteria provided, single submitter clinical testing The c.639+919G>A variant in GLA (also described as c.640-801G>A in the literatur e) has been reported in at least 6 individuals with a later-onset, cardiac varia nt of Fabry disease (Ishii 2002) and in many individuals with hypertrophic cardi omyopathy (HCM) or left ventricular hypertrophy (LVH), all of whom exhibited red uced GLA enzyme activity levels (Ishii 2002, Lin 2009, Lin 2010, Hsu 2016, Kubo 2017). This variant has also been identified by our laboratory in 4 Asian indivi duals with HCM or Fabry disease, and segregated with disease in 3 affected relat ives (2 with Fabry disease and 1 with reduced GLA activity). This variant has be en also been identified in 1/1041 of Asian chromosomes (a hemizygous male) by th e Genome Aggregation Database (gnomAD,; dbSNP rs199473684). Functional studies have shown that the c.639+919G>A variant result s in the accumulation of lamellar bodies and glycosphingolipids in induced pluri potent stem cell cardiomyocytes from a patient with Fabry disease (Chou 2017). I n addition, mRNA slicing studies have shown that this variant leads to abnormal splicing, resulting in the introduction of an additional 57 nucleotides into the GLA transcript, ultimately leading to a truncated protein (Ischii 2002, Palhais 2016, Chang 2017). In summary, the c.639+919G>A variant meets criteria to be cl assified as pathogenic for Fabry disease in an X-linked manner based upon presen ce in multiple affected individuals, functional and segregation studies. ACMG/AM P Criteria applied (Richards 2015): PS3; PS4; PP1.
Invitae RCV000154318 SCV000748692 pathogenic Fabry disease 2018-12-19 criteria provided, single submitter clinical testing This sequence change falls in intron 4 of the GLA gene. It does not directly change the encoded amino acid sequence of the GLA protein. While this variant is not present in population databases, the frequency information is unreliable, as metrics indicate poor data quality at this position in the ExAC database. This variant has been reported as a common cause of Fabry disease and hypertrophic cardiomyopathy in Taiwan, although it has also been reported in other populations (PMID: 11828341, 19621417, 20031620, 22437327, 25611685). This variant is also known as IVS4+919G>A in the literature.  ClinVar contains an entry for this variant (Variation ID: 10768). Experimental studies have shown that this intronic change results in aberrant RNA splicing (PMID: 11828341, 27595546, 28430823). For these reasons, this variant has been classified as Pathogenic.
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000728949 SCV000856576 pathogenic not provided 2017-08-24 criteria provided, single submitter clinical testing
CHEO Genetics Diagnostic Laboratory,Children's Hospital of Eastern Ontario RCV000769537 SCV000900932 pathogenic Cardiomyopathy 2017-07-07 criteria provided, single submitter clinical testing
Blueprint Genetics RCV000728949 SCV000927901 pathogenic not provided 2018-08-31 criteria provided, single submitter clinical testing
OMIM RCV000011515 SCV000031747 uncertain significance Fabry disease, cardiac variant 2002-04-01 no assertion criteria provided literature only
GeneReviews RCV000154318 SCV000494669 pathogenic Fabry disease 2017-01-05 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.